Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Predicting rapid progression and overall survival in stage II-III pancreatic cancer using a CT-based radiomic signature.
Authors
Qinmei Xu
Stanford University School of Medicine, Stanford, CA
Qinmei Xu , Diego Augusto Santos Toesca , Emil Schueler , Arash Jamalian , Emel Alkim , Daniel Tandel Chang , George A. Fisher Jr., Lucas Vitzthum , Olivier Gevaert , Haruka Itakura
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Other
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 706)
DOI
10.1200/JCO.2024.42.3_suppl.706
Abstract #
706
Poster Bd #
N15
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Breakthrough
Utility of radiomic features in predicting clinical outcomes in stage II-III pancreatic cancer.
First Author: Haruka Itakura
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Delta radiomic parameters for the evaluation of liver metastases in patients with colorectal cancer treated with cetuximab rechallenge plus avelumab in the CAVE mCRC study.
First Author: Giulia Martini
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Advanced pancreatic cancer outcomes and the impact of COVID-19 pandemic: The experience of an academic cancer center.
First Author: Christian Adams-Carey
Poster
2023 ASCO Annual Meeting
CT radiomic signature to predict overall survival and chemotherapy benefit in stage I and II HPV-associated oropharyngeal carcinoma.
First Author: Bolin Song